The gap between experimental design and laboratory execution has long been one of the more persistent inefficiencies in molecular biology research. Scientists sketch out cloning strategies, manually transfer information between tools, follow protocols that live in disconnected documents, and spend time reconciling data that should have been linked from the start. Signals BioDesign, developed by Revvity Signals, was built to address exactly that gap — and at the upcoming Signals Connect event, attendees will get a comprehensive look at where the platform stands today and where it is headed next.
About the Session
Event: Signals Connect — Signals BioDesign: What’s New, What’s Next
Date: Wednesday, June 3, 2026
Time: 11:00 AM – 12:00 PM (GMT-4)
Format: Virtual
This one-hour session offers both a live demonstration of Signals BioDesign’s current cloning toolkit and a forward-looking preview of capabilities in active development. It is designed for scientists already using the platform as well as those who are new to it — providing enough depth for experienced users while remaining accessible to those evaluating it for the first time.
The Problem Signals BioDesign Was Built to Solve
Molecular biology workflows have historically been fragmented across tools. Researchers design DNA constructs in one application, record their protocols in another, transfer data to a laboratory information management system (LIMS) manually, and then reconcile their analysis results in yet another environment. Each handoff between systems introduces friction: opportunities for transcription errors, loss of experimental context, delays in reviewing results, and difficulty reproducing work months or years later.
This fragmentation is not merely an inconvenience. In regulated environments — pharmaceutical development, diagnostic assay development, contract research organizations — it represents a compliance and data integrity risk. In academic research settings, it slows down the iterative cycles of design, build, test, and learn that define productive research programs.
Signals BioDesign, first previewed in December 2025 and officially released in March 2026, addresses this by integrating cloning workflow design directly within the Signals One platform — the same environment where experimental data, electronic lab notebooks, and analytical results already live for many life science organizations.
What Signals BioDesign Delivers Today
Since its release in March 2026, Signals BioDesign has evolved rapidly in response to early user feedback. The session will demonstrate the current state of the platform with particular focus on its DNA cloning toolkit, which now includes streamlined workflows for one of the most commonly used assembly methods in modern molecular biology.
Gibson Assembly Workflows
Gibson Assembly has become a standard approach for seamless, multi-fragment DNA cloning — particularly useful for constructing complex plasmid architectures, inserting large sequences, and assembling synthetic gene constructs. In traditional practice, designing a Gibson Assembly involves calculating overlap regions between fragments, verifying that primers will generate compatible ends, and confirming that the final construct sequence is correct before sending designs to synthesis or proceeding to the bench.
Signals BioDesign streamlines this process by enabling researchers to design, visualize, and verify Gibson Assembly strategies within the same digital environment where they manage their broader experimental programs. The session will walk through the end-to-end workflow, from construct design through primer generation to sequence verification.
Integration with Signals One
The integration between Signals BioDesign and Signals One represents the most strategically significant aspect of the platform. Rather than requiring scientists to export their design outputs and manually enter them into a downstream data management system, Signals BioDesign connects directly to the Signals One environment — eliminating the manual data transfer step that has historically been a source of errors and delays.
This means that a construct designed in Signals BioDesign can be directly linked to the experiment record in Signals One that describes how it will be used, the reagents involved, the analytical data generated from its expression, and the conclusions drawn from that analysis. The entire experimental chain — from design intent to final result — lives in a connected, traceable environment.
For organizations operating under quality management systems or GxP requirements, this connectivity has direct compliance implications. For research teams working in less regulated environments, it simply makes science faster and easier to reproduce.
What Is Coming Next
The session’s forward-looking component will preview how Signals BioDesign is becoming more deeply embedded across the Signals ecosystem. While the specifics of upcoming capabilities will be detailed during the live presentation, the direction is clear: tighter integration between construct design, experimental execution, and data analysis — removing more of the remaining manual steps that still require scientists to bridge gaps between tools.
As Signals BioDesign matures, the platform is being positioned not just as a cloning design tool, but as a foundational component of an integrated biologics research environment. For organizations developing antibody therapeutics, gene editing tools, viral vectors, or recombinant protein platforms, the ability to connect construct design to analytical characterization within a single data environment has significant implications for development speed, data quality, and regulatory readiness.
Featured Speakers
Larry Mulcahy, PhD — Product Manager for Biologics, Revvity Signals
Larry Mulcahy leads the development of Signals BioDesign and manages biologics product development for the Signals One platform. He holds a PhD from Brown University and conducted postdoctoral research at Harvard Medical School and Northeastern University, bringing deep molecular and cell biology expertise to his product strategy. Before joining Revvity, he worked in solution consulting for scientific informatics at Thomson Reuters and Benchling, giving him a broad view of the landscape of tools that life science organizations have historically used to manage their research workflows — and where the opportunities for improvement lie.
Mulcahy will lead the live demonstration of the current Signals BioDesign toolkit and provide the preview of upcoming capabilities.
Zev Wisotsky, PhD — Director of Drug Discovery, Biologics Lead, Revvity Signals
Zev Wisotsky brings the perspective of a former bench scientist to his role as Director of Drug Discovery at Revvity Signals. His background spans molecular biology, biochemistry, and drug discovery, and for the past decade he has worked with biotech and pharmaceutical teams to simplify complex scientific workflows and integrate connected software platforms into modern R&D operations.
Wisotsky’s contributions to the session will draw on his direct experience working with biologics research teams, grounding the demonstration in the practical challenges that scientists face when managing cloning workflows at scale.
Who Should Attend
This session is designed to be valuable across a range of roles and experience levels:
- Current Signals BioDesign users looking to understand what capabilities have been added since initial release and what is coming in the near term
- Scientists evaluating cloning workflow software who want a detailed, live view of how Signals BioDesign performs on real workflows
- Informatics and IT leads at life science organizations who need to understand how Signals BioDesign integrates with the broader Signals One environment
- Research managers and lab heads seeking to reduce manual data transfer, improve workflow reproducibility, and consolidate their team’s tool stack
- Biologics and gene therapy teams working on construct design at scale, where connected design-to-analysis workflows would have the greatest impact on development timelines
Attendees from the original December preview session will find meaningful updates to the platform since they last saw it. Those entirely new to Signals BioDesign will leave with a clear picture of what the platform is, how it fits into a broader informatics strategy, and whether it addresses the workflow challenges their teams are currently facing.
Context: The Growing Need for Connected Biology Platforms
The broader industry trend toward integrated, data-connected research platforms has accelerated significantly over the past several years, driven in part by the increasing complexity of modern biologics programs. The emergence of AI-enabled construct design tools, high-throughput screening approaches, and multimodal analytical workflows has increased both the volume of data that research teams must manage and the importance of traceability between experimental decisions and outcomes.
In this environment, tools that operate in isolation — cloning software that does not connect to experimental data, LIMS systems that require manual population, analytical platforms that output data into disconnected file systems — are becoming progressively inadequate. The value proposition of an integrated platform like Signals One, with Signals BioDesign as a key component, lies precisely in its ability to reduce the friction between the stages of the research cycle that have historically required manual bridging.
Signals Connect on June 3 offers an accessible, focused opportunity to evaluate that proposition in practical terms — through a live demonstration of workflows that scientists actually use, presented by the product leaders and drug discovery experts who built and field-tested them.